Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT04745689
Title Study of AZD2811 + Durvalumab in ES-SCLC (TAZMAN)
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors AstraZeneca

lung small cell carcinoma


AZD2811 + Durvalumab

Cisplatin + Durvalumab + Etoposide

Carboplatin + Durvalumab + Etoposide

Age Groups: adult | senior
Covered Countries USA | ESP

No variant requirements are available.